Lidocaine treatment of painful diabetic neuropathy and endogenous opioid peptides in plasma.
Intravenous infusion of lidocaine has a pain-relieving effect in patients with painful diabetic neuropathy. We measured plasma beta-endorphin (beta-EP), dynorphin immunoreactivity (DYN), and met-enkephalin (MET) before and after lidocaine infusion in 8 patients with painful diabetic neuropathy and in 10 controls. The pretreatment level of beta-EP and DYN was identical in the two groups. After lidocaine, beta-EP increased in diabetic patients from 3.4 to 5.5 pmol/L (median) (p less than 0.02) and in controls from 3.4 to 5.0 pmol/L (p less than 0.02). The concentration of DYN was stable, and MET was undetectable before and after lidocaine. Lidocaine reduced symptoms and pain score in diabetic patients was uncorrelated with the changes in beta-EP. Intravenous lidocaine increased plasma beta-EP and diminished complaints in patients with painful diabetic neuropathy.
Kastrup
J
J
Department of Clinical Physiology, Bispebjerg Hospital, Copenhagen, Denmark.
Bach
F W
FW
Petersen
P
P
Dejgård
A
A
Ekman
R
R
Jensen
S
S
Angelo
H
H
D000328:Adult; D003929:Diabetic Neuropathies / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D004399:Dynorphins / Q000097:blood; D004723:Endorphins / Q000097:blood*; D005260:Female; D006801:Humans; D008012:Lidocaine / Q000031:analogs & derivatives / Q000097:blood / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy*; D011863:Radioimmunoassay; D001615:beta-Endorphin / Q000097:blood
D004723:Endorphins; D001615:beta-Endorphin; D004399:Dynorphins; D008012:Lidocaine; C001173:monoethylglycinexylidide